The isobologram summarizes the combination index (CI) at the IC50 when the SMO inhibitor MRT-92 and the BRD4-degrader MZ1 were combined, showing a moderate synergistic anti-proliferative effect (CI < 1) in melanoma cells independently of their BRAF, NRAS, and NF1 mutational status (Fig. 4C, D). The gene discussed is NF1; the disease is melanoma.